Keyword: Gilead Sciences

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

CanSino reports positive data for COVID-19 vaccine. Takeda's Alunbrig wins first-line lung cancer nod. GSK inks $231 million deal with Samsung.

Gilead is working to move CAR-T med Yescarta into other types of NHL, and if data from an interim trial look-in are any indication, it's on its way.

A trial combining Roche's Actemra with Gilead's remdesivir COVID-19 marks the latest in a string of initiatives from Roche to address the pandemic.

The 1,063-patient study showed remdesivir’s benefits look the greatest for individuals in the middle of the disease severity spectrum.

Gilead is already getting requests for national stockpiling of remdesivir, which could mean revenues for years to come.

Interim analysis of a large-scale clinical trial found GSK's twice-monthly cabotegravir is 69% more effective than Truvada in PrEP patients.

For Gilead to prove remdesivir works in moderately ill COVID-19 patients, it will have to show it cuts hospitalization days, JPMorgan warned.

Gilead out-licenses COVID-19 therapy remdesivir. Legend Biotech guns for $100 million Nasdaq IPO. Takeda eyes 12 new drug launches by 2024.